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Purpose: The issue of metabolic risk among patients with schizophrenia 
has received growing attention in recent years, and antipsychotic 
therapies have been implicated. Although a number 
of retrospective observational studies suggest elevated rates of 
diabetes and glucose abnormalities in these patients, endpoint 
definition has been varied and often inaccurate. We sought to 
accurately measure the incidence of diabetes in a prospective 
clinic-based cohort using carefully measured laboratory metabolic 
parameters. 
Methods: A total of 200 schizophrenia (DSM-IV) patients 
free of glucose abnormalities (based on previous normal fasting 
glucose) were enrolled in the ongoing cohort and followed for six 
months. Data collection included general clinical and demographic 
data and extensive metabolic screening (fasting glucose, insulin, 
and oral glucose tolerance tests (OGTT)). Data were collected 
at baseline, three months and six months. Diabetes was defined 
as either a fasting glucose > 126mg/dl or OGGT glucose > 
200 mg/dl at 120 minutes. 
Results: The mean age of the cohort was 37.2 years and 68% 
were male. The mean duration of illness was 14.1 years. The 
majority of patients were treated with clozapine (29%), olanzapine 
(28.4%), risperidone (22.6%), quetiapine (12.1%) or amisulpride 
(7.9%). The six-month incidence of diabetes was 4% (95% CI: 
1.3 6.7%). This is considerably greater than the age-adjusted 
incidence of diabetes in the general population (0.29%). 
Conclusion: The incidence of confirmed new onset diabetes 
among schizophrenia patients previously free of glucose abnormalities 
is much greater than that for the general population. 
Consideration of metabolic risks in schizophrenia patients is 
warranted and requires careful management. 
 
